Ocular Therapeutix, Inc.

NASDAQ:OCUL

Biotechnology

Healthcare
$5.86 -1.17%

-$0.11 today

Market cap
$1.29B
Beta
0.90
P/E (TTM)
-7.3
EPS (TTM)
-$1.30
52W Low $6.23High $16.44

Volume 3.08M

Average 3.00M

Income Statement

Follow revenue through to earnings.

Revenue

$51.82M

FY 2025 · Annual

-18.7% YoY

Operating Income

-$270.02M

FY 2025 · Annual

Net Income

-$265.94M

FY 2025 · Annual

Income Statement

USD
Metric
FY 2021
Dec 2021
FY 2022
Dec 2022
FY 2023
Dec 2023
FY 2024
Dec 2024
FY 2025
Dec 2025
Revenue43.52M51.49M58.44M63.72M51.82M
Cost of Revenue4.41M4.54M5.28M5.63M6.57M
Gross Profit39.12M46.95M53.16M58.1M45.25M
Gross Margin89.9%91.2%91.0%91.2%87.3%
Research & Development50.08M53.46M61.06M127.64M197.1M
Selling, General & Admin67.07M72.15M74.49M102.24M118.3M
Operating Expenses117.15M125.61M135.54M229.88M315.39M
Depreciation & Amortization2.42M2.11M2.98M3.79M4.32M
EBITDA2.54M(61.91M)(66.42M)(176.14M)(249.78M)
EBITDA Margin5.8%-120.2%-113.6%-276.4%-482.0%
Operating Income(78.04M)(78.65M)(82.38M)(171.78M)(270.02M)
Operating Margin-179.3%-152.7%-141.0%-269.6%-521.0%
Interest Income33K798K3.98M20.28M18.36M
Interest Expense6.67M7.02M11.34M13.58M11.84M
Other Income / Expenses71.48M7.62M1.65M(21.73M)4.08M
Income Before Tax(6.55M)(71.04M)(80.74M)(193.51M)(265.94M)
Pre-Tax Margin-15.1%-138.0%-138.1%-303.7%-513.2%
Income Tax Expense00000
Net Income(6.55M)(71.04M)(80.74M)(193.51M)(265.94M)
Net Margin-15.1%-138.0%-138.1%-303.7%-513.2%
EPS (Basic)(1.05)(1.04)(1.09)(1.22)(1.42)
EPS (Diluted)(0.98)(0.97)(1.02)(1.22)(1.42)
Weighted Avg Shares76.39M76.88M79.83M158.27M187.24M
Weighted Avg Shares (Diluted)82.16M82.64M85.6M158.27M187.24M

OCUL Earnings Waterfall · TTM

NASDAQ:OCUL · Revenue to Net Income

Key Ratios

EPS$-1.46
Gross Margin87.3%
Net Margin-572.7%
P/E Ratio-7.4
P/S Ratio161.8

Analysis

$52.0M of revenue converted into -$290.5M of net income for the selected period. Gross margin is 87.3% and net margin is -572.7%, showing how much revenue survives after costs and taxes. EPS is $-1.46, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipNov 10, 2026
3Initial statement of beneficial ownershipNov 10, 2026
8-KCurrent reportNov 9, 2026
4Statement of changes in beneficial ownershipNov 9, 2026
10-QQuarterly reportNov 9, 2026

How much revenue does OCUL generate?

Ocular Therapeutix, Inc. (OCUL) reported $51.82M of revenue in fiscal 2025.

Is OCUL profitable?

Ocular Therapeutix, Inc. (OCUL) reported -$265.94M of net income, with a net margin of -513.2%.